Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
C-X-C Chemokine Receptor Type 2 Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The c-x-c chemokine receptor type 2 market has seen rapid expansion in recent years. It is projected to grow from $1.38 billion in 2025 to $1.55 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.8%. Historically, the market’s expansion can be ascribed to factors including a limited understanding of cxcr2 biology, a reliance on conventional anti-inflammatory drugs, increasing research into chemokine signaling, the early-stage development of monoclonal antibodies, and a growing prevalence of inflammatory diseases.
The c-x-c chemokine receptor type 2 market is projected to witness significant growth over the next few years, expanding to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. This anticipated growth can be attributed to factors such as the development of novel small molecule and peptide inhibitors, an expansion of clinical trials for CXCR2 therapies, the increasing adoption of personalized and targeted immunotherapies, the integration of digital biomarkers and AI-based drug discovery, and rising pharmaceutical investment in oncology and autoimmune markets. Key trends expected in the forecast period include the development of selective CXCR2 inhibitors and dual CXCR1/2 inhibitors, advancements in monoclonal antibody and peptide-based therapeutics, the expansion of applications in cancer, autoimmune, and inflammatory diseases, growth in gene therapy and RNA-based therapeutics targeting CXCR2, and the integration of CXCR2 targeted therapies with personalized medicine approaches.
Get A Free Sample Report With In-Depth Market Insights:
C-X-C Chemokine Receptor Type 2 Market Demand Drivers Opening New Revenue Streams
The growing occurrence of inflammatory conditions is projected to stimulate the expansion of the C-X-C chemokine receptor type 2 market in the future. Inflammatory conditions are medical disorders stemming from the body’s immune response, characterized by swelling, redness, heat, pain, and functional impairment in affected tissues or organs. The increase in inflammatory conditions is primarily driven by rising environmental pollution, which triggers immune system reactions and chronic inflammation. C-X-C Chemokine Receptor Type 2 (CXCR2) supports treatments for these conditions by precisely regulating immune cell movement and inflammatory responses. It reduces unintended side effects by enabling small-molecule inhibitors and biologics that specifically modulate CXCR2 activity, thereby enhancing treatment efficacy and patient outcomes. For instance, in May 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the prevalence of asthma among adults aged 18 and over in the United States increased from 8.7% in 2022 to 8.9% in 2023. Consequently, the rising prevalence of inflammatory conditions is fueling the growth of the C-X-C chemokine receptor type 2 market. A heightened emphasis on targeted therapies is anticipated to drive the C-X-C chemokine receptor type 2 market’s growth going forward. Targeted therapies are treatments designed to specifically identify and inhibit molecular abnormalities in cancer or other diseases, aiming to improve treatment precision and minimize harm to healthy cells. The increasing focus on targeted therapies is mainly propelled by advancements in precision medicine, which facilitates personalized, more effective treatments based on individual genetic profiles. C-X-C chemokine receptor type 2 enables targeted therapies by guiding immune responses, supporting precise treatments for autoimmune and inflammatory diseases. It supports precision medicine by allowing the development of small-molecule inhibitors and biologics that specifically modulate CXCR2 activity, improving therapeutic efficacy and reducing off-target effects. For instance, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved 6 gene therapy products in 2023, an increase from 5 approvals in 2022. Therefore, the increasing focus on targeted therapies is driving the growth of the C-X-C chemokine receptor type 2 market.
C-X-C Chemokine Receptor Type 2 Market Segment Trends And Revenue Contributors
The c-x-c chemokine receptor type 2 market covered in this report is segmented –
1) By Product Type: Antagonists, Agonists, Inhibitors, Other Product Types
2) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Peptide-based Therapeutics, Gene Therapy Products
3) By Route Of Administration: Intravenous, Subcutaneous, Oral, Topical
4) By Application: Cancer Treatment, Autoimmune Disorders, Infectious Diseases, Inflammatory Diseases, Other Applications
5) By End User: Hospitals, Research Institutions, Pharmaceutical Companies, Contract Research Organizations, Other End Users
Subsegments:
1) By Antagonists: Small Molecule Antagonists, Peptide Antagonists, Monoclonal Antibody Antagonists, Synthetic Antagonists
2) By Agonists: Chemokine-Based Agonists, Recombinant Protein Agonists, Peptide-Based Agonists, Modified Cytokine Agonists
3) By Inhibitors: Selective CXCR2 Inhibitors, Dual CXCR1 Or 2 Inhibitors, Allosteric Inhibitors, Irreversible Inhibitors
4) By Other Product Types: RNA-Based Therapeutics, Gene Therapy Vectors, Cell-Based Therapeutics, Biologic Response Modifiers
C-X-C Chemokine Receptor Type 2 Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the c-x-c chemokine receptor type 2 market are AstraZeneca plc, GSK plc, Eli Lilly and Company, Bio-Techne Corporation, Dompé Farmaceutici S.p.A., Miltenyi Biotec B.V. & Co. KG, Abcam plc, Selleck Chemicals LLC, Cell Signaling Technology Inc., RayBiotech Inc., Bethyl Laboratories Inc., Creative Biolabs Inc., TargetMol LLC, MedChemExpress LLC, BioCompare Inc., Boster Biological Technology Co. Ltd., TME Pharma GmbH, InvivoChem Ltd., Abbexa Ltd., Abiocode Inc.
View The Full C-X-C Chemokine Receptor Type 2 Market Report:
C-X-C Chemokine Receptor Type 2 Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the C-X-C chemokine receptor type 2 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c-x-c chemokine receptor type 2 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model